## Abstract ## Purpose To intraindividually compare the enhancement pattern of focal nodular hyperplasia (FNH) after dynamic administration of two bolus‐injectable liver‐specific MR contrast agents, ferucarbotran and gadobenate dimeglumine. ## Materials and Methods A total of 19 patients with 24
Gadobenate dimeglumine–enhanced magnetic resonance imaging of primary leiomyoma of the liver
✍ Scribed by Daniele Marin; Carlo Catalano; Massimo Rossi; Antonino Guerrisi; Michele Di Martino; Pasquale Berloco; Roberto Passariello
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 393 KB
- Volume
- 28
- Category
- Article
- ISSN
- 1053-1807
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
We report a case of histologically proven primary leiomyoma of the liver that was evaluated with multiphasic 64‐section computed tomography (CT) and gadobenate dimeglumine–enhanced magnetic resonance (MR) imaging. This lesion showed vivid enhancement during the arterial phase with sustained enhancement during the hepatic venous and equilibrium phases. During the liver‐specific MR imaging phase (150 minutes after contrast injection), the same lesion demonstrated lack of contrast retention, thus appearing hypointense compared with the background liver. Because of this latter finding, the patient underwent partial resection of the liver. In primary hepatic leiomyoma, the absence of contrast uptake during the liver‐specific phase of gadobenate dimeglumine–enhanced MR imaging may be inappropriately interpreted as a sign of malignancy, thus leading to unnecessary, aggressive management of such lesions. J. Magn. Reson. Imaging 2008;28:755–758. © 2008 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract To determine whether gadobenate dimeglumine (BOPTA) will adequately enhance cirrhotic liver parenchyma, and to document the enhancement patterns in cirrhosis, 14 cirrhotic and 20 non‐cirrhotic patients were evaluated before and 60–120 minutes after gadolinium‐BOPTA. Proof of liver cirrh
## Abstract Seventy‐four patients with one to eight proven intraaxial metastatic lesions to the brain received a total gadobenate dimeglumine dose of 0.3 mmol/kg of body weight, administered as three sequential bolus injections of 0.1 mmol/kg, at 10‐minute intervals over a 20‐minute period. Quantit
## Abstract ## Purpose To compare gadoxetic acid disodium (Gd‐EOB‐DTPA)‐enhanced magnetic resonance imaging (MRI) with gadobenate dimeglumine (Gd‐BOPTA)‐enhanced MRI in preoperative living liver donors for the evaluation of vascular and biliary variations. ## Materials and Methods Sixty‐two livi
## Abstract ## Purpose: To compare the image quality and diagnostic performance of 1‐ and 3‐h delayed‐phase MR images (DPIs) after gadobenate dimeglumine injection in detecting small hepatocellular carcinomas (HCCs) in cirrhotic patients. ## Materials and Methods: Relative enhancement of the liv
## Purpose: To investigate and assess the radiologic, serological, and histopathologic findings in patients who presented with early heterogeneous enhancement (ehe) on gadolinium-enhanced early-phase magnetic resonance imaging (mri) of the liver. ## Materials and methods: We searched our radiolog